Next Article in Journal
Supramolecular Complexes of β-Cyclodextrin with Clomipramine and Doxepin: Effect of the Ring Substituent and Component of Drugs on Their Inclusion Topologies and Structural Flexibilities
Next Article in Special Issue
Kinin B2 Receptor Activation Prevents the Evolution of Alzheimer’s Disease Pathological Characteristics in a Transgenic Mouse Model
Previous Article in Journal
Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
Previous Article in Special Issue
Molecular Features of Non-Selective Small Molecule Antagonists of the Bradykinin Receptors
Open AccessArticle

Pharmacological Modulation of Blood–Brain Barrier Permeability by Kinin Analogs in Normal and Pathologic Conditions

1
Department of Nuclear Medicine & Radiobiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
2
Department of Pharmacology & Physiology, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
3
Department of Pharmacology & Physiology, Université de Montréal, Montréal, QC H2X 0A9, Canada
4
Department of Surgery, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(10), 279; https://doi.org/10.3390/ph13100279
Received: 20 August 2020 / Revised: 23 September 2020 / Accepted: 24 September 2020 / Published: 29 September 2020
The blood–brain barrier (BBB) is a major obstacle to the development of effective diagnostics and therapeutics for brain cancers and other central nervous system diseases. Peptide agonist analogs of kinin B1 and B2 receptors, acting as BBB permeabilizers, have been utilized to overcome this barrier. The purpose of the study was to provide new insights for the potential utility of kinin analogs as brain drug delivery adjuvants. In vivo imaging studies were conducted in various animal models (primary/secondary brain cancers, late radiation-induced brain injury) to quantify BBB permeability in response to kinin agonist administrations. Results showed that kinin B1 (B1R) and B2 receptors (B2R) agonists increase the BBB penetration of chemotherapeutic doxorubicin to glioma sites, with additive effects when applied in combination. B2R agonist also enabled extravasation of high-molecular-weight fluorescent dextrans (155 kDa and 2 MDa) in brains of normal mice. Moreover, a systemic single dose of B2R agonist did not increase the incidence of metastatic brain tumors originating from circulating breast cancer cells. Lastly, B2R agonist promoted the selective delivery of co-injected diagnostic MRI agent Magnevist in irradiated brain areas, depicting increased vascular B2R expression. Altogether, our findings suggest additional evidence for using kinin analogs to facilitate specific access of drugs to the brain. View Full-Text
Keywords: kinin analogs; G protein-coupled receptors; blood–brain barrier permeability; chemotherapy; radiotherapy; CNS diseases kinin analogs; G protein-coupled receptors; blood–brain barrier permeability; chemotherapy; radiotherapy; CNS diseases
Show Figures

Graphical abstract

MDPI and ACS Style

Sikpa, D.; Whittingstall, L.; Savard, M.; Lebel, R.; Côté, J.; McManus, S.; Chemtob, S.; Fortin, D.; Lepage, M.; Gobeil, F. Pharmacological Modulation of Blood–Brain Barrier Permeability by Kinin Analogs in Normal and Pathologic Conditions. Pharmaceuticals 2020, 13, 279.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop